Abstract
Aim: W1282X is the sixth most common cystic fibrosis (CF)-causing variant and one of those without an approved therapy. Adenine base editing (ABE) has attracted interest as it can correct mutations without creating a double-stranded break in DNA, being thus potentially safer than the traditional approach with CRISPR/Cas9. Efficient correction of W1282X by ABE has been reported but bystander edits have been observed at the adjacent adenines.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
